Skip to main content
. 2007 Feb 12;64(1):67–74. doi: 10.1111/j.1365-2125.2007.02846.x

Table 3.

Pharmacokinetic parameters of gliclazide in subjects with various CYP2C9 genotypes in the single-dose study (mean and 95% CI)

Parameters CYP2C9*1/*1 (n = 13) CYP2C9*1/*3 (n = 8) CYP2C9*1/*13 (n = 3)
AUC0−72 (µg ml−1 h−1) 26.9 (18.5, 35.2) 21.5 (15.5, 27.6) 46.8 (−0.88, 94.6)
AUC0–∞ (µg ml−1 h−1) 30.4 (18.5, 42.3) 23.3 (16.5, 30.0) 65.6 (−33.4, 164.7)
Cmax (µg ml−1) 1.32 (0.83, 1.81) 0.906 (0.636, 1.18) 1.63 (1.18, 2.08)
tmax (h) 9.08 (7.81, 10.4) 9.75 (8.28, 11.2) 10.7 (3.07, 18.3)
t1/2 (h) 18.7 (11.6, 25.8) 16.7 (13.9, 19.5) 33.5 (−18.9, 86.0)